Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pilot Study of [18F]F AraG PET Imaging for Immunological Response to Checkpoint Inhibitor Therapy in Advanced Solid Tumors
NCT04260256Phase 2Terminated
- Sponsor
- CellSight Technologies
- Start
- Mar 2022
- Primary completion
- Mar 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of [18F]fluoro-arabinofuranosyl guanine in solid tumor, sponsored by CellSight Technologies. Started Mar 2022; status: terminated.
02
Drugs
[18F]fluoro-arabinofuranosyl guanine
03
Conditions
solid tumor
Beyond the preview
Go deeper on NCT04260256.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04260256.